Business

Bristol Myers Squibb Partners with Hengrui Pharma

Updated 2026-05-12 08:00 UTC 1 source Neutral

Bristol Myers Squibb and China’s Hengrui Pharma have entered into a significant partnership to advance over a dozen early-stage drugs, valued at up to $15.2 billion.

Coverage timeline — 1 article

STAT News

STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs

Bristol Myers Squibb and China's Hengrui Pharma are teaming up to advance more than a dozen early-stage drugs, in a deal worth up to $15.2 billion.

2026-05-12 07:48 UTC